News Background

Oxford, UK – 30 January 2012. Professor Sir Ed Southern, founder of OGT, a provider of innovative genetics research and biomarker solutions to advance molecular medicine, has been awarded the 2011 Medical Research Council (MRC) Millennium Medal. Sir Ed becomes one of only four researchers to have received the prize since it was inaugurated in the year 2000, which recognises an MRC-funded scientist whose outstanding research has made a major contribution towards the health and wealth of our society. Described by Professor Anthony Hamilton, vice-chancellor of the University of Oxford, as a “scientist, innovator, entrepreneur and philanthropist”, Sir Ed’s work developing the technology underpinning modern DNA microarrays, has “transformed healthcare and improved the lives of many patients” according to MRC chief executive Sir John Savill.

Upon receiving the MRC Millennium Medal, Sir Ed said: “I am greatly thankful for the support of the Medical Research Council. The MRC has very high standards, and to be funded by them is a commendation in itself.” Sir Ed has made major contributions to the field of DNA research, and in 1975 invented a revolutionary technique for identifying whether specific sequences are contained in a sample of DNA, which became known subsequently as the ‘Southern Blot’. Commenting on Sir Ed’s pioneering work, Sir John Savill suggested that “without the blotting technique, so many other discoveries and advances would not have been made.” A second invention, based on the attachment of a multitude of specific DNA probes to a solid substrate, laid the groundwork for the development of modern DNA microarrays, which allow the entire human genome to be investigated quickly and easily. This approach has many applications in genomic research, clinical diagnosis and drug discovery, and has subsequently spawned an industry worth billions of pounds.

In 1995, Sir Ed founded the biotechnology company OGT, with the mission of developing advanced molecular tools for biologists. By leveraging its world class expertise in microarray technology and genomic data analysis, the company provides high quality products and services for use in cytogenetics research, genome wide association studies and copy number variation (CNV) detection. The company has also recently invested in developing a targeted sequencing service and a novel biomarker discovery platform that uses protein-based array technology. By combining these research solutions, customers have access to a complete genomic analysis and biomarker discovery toolkit that provides high quality data using independently accredited laboratory procedures. In addition to holding the roles of Chairman and Chief Scientific Officer, Sir Ed also leads OGT’s Exploratory Research group which seeks to provide innovative solutions to scientific problems, including single cell analysis, single molecule imaging and cancer mutation screening.  Sir Ed has also established two charities: the Kirkhouse Trust which works to improve crops in semi-arid regions of East and West Africa; and the Edina Trust which promotes and funds science in schools.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

  • Share

You might also be interested in

OGT pledges partnership with significant brand refresh and integration Listing Image

OGT pledges partnership with significant brand refresh and integration

24 Mar 2021

New integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.

Read
OGT's NGS panels to be featured in user workshop at AMP 2020 Listing Image

OGT's NGS panels to be featured in user workshop at AMP 2020

09 Nov 2020

In the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.

Read
OGT expands NGS cancer panel offering Listing Image

OGT expands NGS cancer panel offering

03 Nov 2020

Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter